

1 **Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in**  
2 **Severe COVID-19**

3  
4 Mustafa Buyukozkan<sup>1,2\*</sup>, Sergio Alvarez-Muletti<sup>3\*</sup>, Alexandra C. Racanelli<sup>3\*</sup>, Frank  
5 Schmidt<sup>4</sup>, Richa Batra<sup>1,2</sup>, Katherine L. Hoffman<sup>5</sup>, Hina Sarwath<sup>4</sup>, Rudolf Engelke<sup>4</sup>, Luis  
6 Gomez-Escobar<sup>3</sup>, Will Simmons<sup>5</sup>, Elisa Benedetti<sup>1,2</sup>, Kelsey Chetnik<sup>1,2</sup>, Guoan Zhang<sup>6</sup>,  
7 Edward Schenck<sup>3</sup>, Karsten Suhre<sup>7</sup>, Justin J. Choi<sup>8</sup>, Zhen Zhao<sup>9</sup>, Sabrina Racine-  
8 Brzostek<sup>9</sup>, He S. Yang<sup>9</sup>, Mary E. Choi<sup>10</sup>, Augustine M.K. Choi<sup>3</sup>, Soo Jung Cho<sup>3#</sup>,  
9 Jan Krumsiek<sup>1,2#</sup>

10  
11 <sup>1</sup>Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA

12 <sup>2</sup>Meyer Cancer Center and Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell  
13 Medicine, New York, NY, USA

14 <sup>3</sup>Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine,  
15 New York, NY, USA

16 <sup>4</sup>Proteomics Core, Weill Cornell Medicine – Qatar, Doha, Qatar

17 <sup>5</sup>Department of Population Health Sciences, Division of Biostatistics, Weill Cornell Medicine, New  
18 York, NY, USA

19 <sup>6</sup>Proteomics and Metabolomics Core Facility, Weill Cornell Medicine, New York, NY, USA

20 <sup>7</sup>Department of Physiology and Biophysics, Weill Cornell Medicine – Qatar, Education City, 24144  
21 Doha, Qatar

22 <sup>8</sup>Department of Medicine, Division of General Internal Medicine, Weill Cornell Medicine, New York,  
23 NY, USA

24 <sup>9</sup>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

25 <sup>10</sup>Division of Nephrology and Hypertension, Joan and Sanford I. Weill Department of Medicine, New  
26 York, NY, USA

27  
28 \* these authors contributed equally to this work

29 # corresponding authors

30  
31 Correspondence to:

32 Soo Jung Cho, [sjc9006@med.cornell.edu](mailto:sjc9006@med.cornell.edu)

33 Jan Krumsiek, [jak2042@med.cornell.edu](mailto:jak2042@med.cornell.edu)

## 34 **Abstract**

35 The novel coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has  
36 ravaged global healthcare with previously unseen levels of morbidity and mortality. To  
37 date, methods to predict the clinical course, which ranges from the asymptomatic carrier  
38 to the critically ill patient in devastating multi-system organ failure, have yet to be  
39 identified. In this study, we performed large-scale integrative multi-omics analyses of  
40 serum obtained from COVID-19 patients with the goal of uncovering novel pathogenic  
41 complexities of this disease and identifying molecular signatures that predict clinical  
42 outcomes. We assembled a novel network of protein-metabolite interactions in COVID-  
43 19 patients through targeted metabolomic and proteomic profiling of serum samples in  
44 330 COVID-19 patients compared to 97 non-COVID, hospitalized controls. Our network  
45 identified distinct protein-metabolite cross talk related to immune modulation, energy and  
46 nucleotide metabolism, vascular homeostasis, and collagen catabolism. Additionally, our  
47 data linked multiple proteins and metabolites to clinical indices associated with long-term  
48 mortality and morbidity, such as acute kidney injury. Finally, we developed a novel  
49 composite outcome measure for COVID-19 disease severity and created a clinical  
50 prediction model based on the metabolomics data. The model predicts severe disease  
51 with a concordance index of around 0.69, and furthermore shows high predictive power  
52 of 0.83-0.93 in two previously published, independent datasets.

53

## 54 **Introduction**

55 The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical  
56 features that range from asymptomatic disease to acute respiratory distress syndrome  
57 (ARDS)(1, 2). COVID-19 ARDS can lead to refractory hypoxia, mechanical ventilation,  
58 prolonged intensive care unit (ICU) stay and increased mortality(3). Previous studies have  
59 shown a high incidence of concomitant organ failure in COVID-19, including acute kidney  
60 injury (AKI)(4), acute liver injury(5), thromboembolic events(6, 7) and secondary  
61 infections contributing to a fatal outcome(8).

62 Massive investigative efforts by multiple scientific groups have used proteomic and  
63 metabolomic approaches to begin to unravel disease mechanisms relevant to SARS-

64 CoV-2 infection such as inflammation, coagulation, and metabolism(9). However, how  
65 COVID-19 specific protein-metabolite interactions relate to the severity of disease and  
66 clinical outcomes remains poorly understood. Key study limitations have included  
67 relatively small sample sizes, absence of protein-metabolite network analysis and the  
68 focus on dichotomous outcome measures such as death and survival. These limitations  
69 have been difficult to overcome and restrict our understanding of COVID-19  
70 pathogenesis.

71 Here, we report the largest study to integrate targeted metabolomic and proteomic  
72 analyses of serum samples obtained from hospitalized COVID-19 patients during SARS-  
73 CoV-2 infection compared to patients admitted during the same time period with  
74 symptoms related to COVID-19 and negative RT-PCR for SARS-CoV-2 as controls  
75 (Figure 1). Through this work, we uncovered COVID-19-specific metabolite and protein  
76 profiles, identified novel protein-metabolite modules, and defined the molecular  
77 signatures of several clinical indices (CRP, ferritin, platelet count, AKI, and death).  
78 Additionally, we developed the first clinical composite outcome prediction model in  
79 COVID-19, where the input of discrete metabolic profiles significantly improves our clinical  
80 insight into a broad range of outcomes known to plague many survivors of severe COVID-  
81 19.

## 82 **Results**

### 83 **Study cohort and dataset**

84 Our cohort was comprised of 330 patients with confirmed SARS-CoV-2 RT-PCR, and 97  
85 non-COVID-19 controls with negative RT-PCR results who were hospitalized at the  
86 NewYork-Presbyterian Hospital/Weill Cornell Medical Center between March and April  
87 2020. Serum samples were obtained within the first 3 days of admission. The majority of  
88 COVID-19 patients had samples drawn at two or three different time points resulting in a  
89 total of 582 serum samples from the 330 COVID-19 patients, while all 97 controls had  
90 one sample drawn. Metabolomics was measured for all available samples. Proteomics  
91 was measured for fewer samples (n=189), also across different time points for some  
92 patients. Notably, there were only minor time effects across the three days  
93 (Supplementary Figure 1), and the repeated samples were thus treated as replicates

94 using a linear mixed effect model, see Methods. A detailed description of the clinical and  
95 demographic characteristics of the cohort can be found in Table 1, Supplementary  
96 Table 1 and Supplementary Table 2. Of note, we excluded samples collected after  
97 intubation because we found that the clinical act of intubation significantly alters a  
98 patient's metabolic profile (Supplementary Table 3).

99 Metabolic profiles were assessed for all samples using liquid chromatography coupled  
100 with mass spectrometry (LC/MS). After quality control and data preprocessing, 125  
101 metabolites were available for comparative analysis. Targeted proteomic profiling was  
102 performed on a subset of 227 samples (173 from COVID-19 patients and 54 controls)  
103 using the Olink inflammation, cardiovascular II and cardiovascular III panels, which cover  
104 266 unique protein biomarkers. These panels were selected since it has previously been  
105 shown that inflammation and cardiovascular pathways are essential during COVID-19  
106 pathogenesis(10).

107

### 108 **Metabolomic and proteomic changes associated with COVID-19**

109 Differential metabolomic analysis identified significant changes in abundance of 70 out of  
110 the 125 analyzed metabolites between COVID-19 and controls at a false discovery rate  
111 (FDR) of 0.05 (Figure 2A). The top three differentially expressed metabolites were  
112 involved in amino acid metabolism: N-acetyl-L-aspartic acid (p-value = 9.19E-18), N-  
113 acetyl-aspartyl-glutamic acid (p-value = 5.30E-15), and argininosuccinic acid (p-value =  
114 6.35E-12) (Figure 2B). KEGG pathway mapping of the differentially expressed  
115 metabolites revealed an involvement of various metabolic pathways (Figure 2C). These  
116 pathways included arginine and proline metabolism, glycine and serine metabolism,  
117 alanine metabolism, methionine metabolism, sphingolipid metabolism, gluconeogenesis,  
118 and the TCA cycle pathway, demonstrating involvement of the broader categories of  
119 amino acid, lipid and energy metabolism in COVID-19 pathogenesis. Our results confirm  
120 prior reports that reported altered phenylalanine and tryptophan metabolism in severe  
121 COVID-19 patients compared to non-COVID-19 patients(11-13). Additionally, our data  
122 has shown that multiple metabolites involved in sphingolipid metabolism are significantly

123 increased in COVID-19 patients, pointing towards other potential targets for COVID-19  
124 treatment(14).

125 Comparative proteomic analysis identified significant changes in the expression of 48 out  
126 of the 266 analyzed proteins between COVID-19 and controls at an FDR of 0.05  
127 (Figure 2D). The top three differentially expressed proteins were C-X-C motif chemokine  
128 ligand 10 (CXCL10) (p-value = 5.09E-13), galectin 9 (Gal-9) (p-value = 5.49E-10), and  
129 monocyte chemoattractant protein 3 (MCP-3) (p-value = 2.85E-09) (Figure 2E). KEGG  
130 pathway mapping revealed that these proteins participated in various protein pathways  
131 (Figure 2F), including the interleukin 17 (IL-17), tumoral necrosis factor (TNF) and JAK-  
132 STAT signaling pathways. Detailed results of the differential analysis and pathway  
133 mappings can be found in Supplementary Table 4. Of note, the utility of the JAK inhibitors  
134 baricitinib or ruxolitinib has already been demonstrated in a clinical trial for selected  
135 patients with severe or critical COVID-19 patients(15, 16). Based on our data, clinical  
136 trials further targeting IL-17 and TNF signaling in COVID-19 may lead to additional  
137 therapeutic approaches for treating COVID-19.

138 Global principal component analysis (PCA) on the metabolomics and proteomics data  
139 revealed no clear separation of COVID-19 and control groups (Supplementary Figure 2).  
140 This is an effect that we have commonly observed in previous studies of blood data(17-  
141 22), where omics profiles only separated groups in a specific (single molecules and  
142 pathways) rather than a global fashion.

143

#### 144 **Protein-metabolite networks identify potential mediators of COVID-19 pathology**

145 To obtain further mechanistic insight into the biology of COVID-19, we developed a  
146 comprehensive, data-driven network for the integrative analysis of our multi-omics  
147 dataset. We first generated a Gaussian graphical model (GGM) of correlated metabolites  
148 and proteins from our COVID-19 cohort (Supplementary Data 1). GGMs are correlation-  
149 based network models that we have previously demonstrated to accurately reconstruct  
150 biological pathways from blood-based omics data(23-25). A minimum spanning tree-  
151 based algorithm was then used to identify a focused subnetwork that connects the most

152 significantly correlated metabolites and proteins from the original network (Figure 3). The  
153 subnetwork included 13 proteins from the Olink inflammatory panel, 32 proteins from the  
154 Olink cardiovascular panels II and III, and 70 metabolites. From this subnetwork, we  
155 selected 4 network modules to query the interplay between metabolism, inflammation,  
156 and vascular dysfunction in COVID-19 patients.

157 *Inflammation-related network modules. Module 1.* Our network identified  
158 hexanoylcarnitine as a key metabolite associated with inflammatory cytokines in COVID-  
159 19 illness. The module contained IFN-gamma, CXCL10 and CXCL11 that were all  
160 upregulated in COVID-19 and associated with hexanoylcarnitine. IFN-gamma, CXCL10  
161 and CXCL11 are proinflammatory cytokines which regulate T cell immunity(26), while  
162 hexanoylcarnitine is a medium-chain fatty acid conjugate that plays a critical role in  
163 energy metabolism and mitochondrial fatty acid  $\beta$ -oxidation (Figure 3)(27). Levels of other  
164 carnitine species (L-carnitine and caprylic acid) were also elevated in COVID-19 patients,  
165 suggesting a role for inflammation, dysregulated fatty acid  $\beta$ -oxidation and mitochondrial  
166 dysfunction in COVID-19 pathogenesis(12, 28-31).

167 *Module 2.* In a second inflammation-related module, cytosine was another key metabolite  
168 linked with inflammatory cytokines during COVID-19. The module consisted of a group of  
169 macrophage-derived cytokines, including MCP-2, MCP-3 and GRN, which were all  
170 upregulated in COVID-19 and positively associated with cytosine (Figure 3). This finding  
171 is consistent with the hyperinflammatory state of COVID-19 infection in which cytokine  
172 storm is often observed(32). Cytosine, a pyrimidine-class nucleotide that is an essential  
173 metabolite for cell proliferation and survival, is commonly upregulated in the host  
174 response during viral infection and is furthermore an important mediator of viral  
175 replication(33). Prior reports have shown cytosine levels to be elevated in COVID-19  
176 patients(34), which was corroborated in our own cohort. Taken together, cytosine may be  
177 a key metabolite linking viral replication to SARS-CoV-2 induced inflammation.

178 *Vascular-related network modules. Module 3.* While COVID-19 presents itself mainly as  
179 a respiratory disease, autopsy reports have additionally described significant vascular  
180 injury due to endothelial cell damage, microcirculatory thrombi, and impaired cellular  
181 junction integrity(35). Our network uncovered the coordination of MERTK, RAGE and

182 thrombomodulin (TM) with the metabolite 4-hydroxyproline in COVID-19 (Figure 3).  
183 MERTK, RAGE and TM are proteins key to maintaining features of endothelial  
184 homeostasis, and hydroxyproline is a major component of collagen(36). MERTK, a  
185 member of the TAM family of receptor tyrosine kinases (RTKs), and RAGE, a pro-  
186 coagulant and inflammatory molecule were upregulated, while TM was downregulated,  
187 suggesting induction of a pro-coagulant and inflammatory vascular state in COVID-19.  
188 Notably, the coordination of these proteins centered around alterations in levels of  
189 hydroxyproline, where downregulation of TM directly correlated with hydroxyproline  
190 levels. A link between TM and hydroxyproline has been described, where administration  
191 of TM had anti-fibrotic effects on lung and kidney murine models(37). Taken together,  
192 these data link the pro-coagulant and fibrotic state of COVID-19 through thrombomodulin  
193 and hydroxyproline.

194 *Module 4.* In a second vascular-related module, we found that cathepsin D (CTSD), a  
195 lysosomal protease known to disrupt endothelial cell junctions and increase  
196 vasopermeability, was associated with a group of glycolytic metabolites including  
197 D-glucose, glycerol-3-phosphate, and lactic acid(38). Notably, increased vascular  
198 permeability and glycolysis are known features of a pro-angiogenic state(39). While  
199 dysregulated angiogenesis occurs in COVID-19 patients(40), how these events are  
200 coordinated remains poorly understood. Here, we report the concomitant up-regulation of  
201 cathepsin D and intermediate products of glycolysis (D-glucose and lactic acid) in our  
202 COVID-19 cohort, which position this enzyme as a potential driver of the COVID-19  
203 phenotype. Of note, elevated plasma activity of cathepsin D has been found in patients  
204 with type 2 diabetes, suggested a link between abnormal vasculature and the  
205 dysregulated glucose metabolism seen in our higher risk diabetic COVID-19 patients(41).  
206 Taken together these data suggest that the disruption of vascular and glucometabolic  
207 homeostasis in COVID-19 is mediated by cathepsin D.

208

#### 209 **Serum metabolites and proteins associate with clinical indices in COVID-19**

210 Serum metabolites and proteins within the COVID-19 patient group were assessed for  
211 correlation with relevant clinical indices including: i) demographics (sex, age, BMI), ii)

212 concurrent comorbidity (hypertension, pre-existing kidney disease, diabetes mellitus  
213 [DM], severity of illness [SOFA]), iii) laboratory markers of inflammation (C-reactive  
214 protein [CRP], d-dimer, lymphocyte count, platelet count, ferritin), and iv) future clinical  
215 events (ARDS, death) (Figure 4A and 4D). Pre-existing kidney disease was found to  
216 associate with the highest number of both metabolites and proteins. Other clinical  
217 parameters including ARDS, death, BMI, gender, age, SOFA score, hypertension, DM,  
218 and d-dimer levels were associated with numerous metabolites but only few proteins.  
219 Conversely, platelet count and ferritin level were associated with a large number of  
220 proteins but relatively few metabolites. Detailed association results are provided in  
221 Supplementary Tables 5 and 6.

222 Hierarchical clustering of clinical indices by their correlation with metabolites revealed two  
223 broad clusters: one predominantly related to laboratory markers of inflammation, and a  
224 second largely related to non-laboratory indices (Figure 4B). Volcano plots of three  
225 representative indices (death, pre-existing kidney disease and CRP) are shown in  
226 Figure 4C. Seventy-five metabolites were significantly associated with death, 96 with pre-  
227 existing kidney disease and 37 with CRP level. 69 metabolites were associated with both  
228 death and kidney disease and 20 were associated with death, kidney disease and CRP  
229 levels. Key metabolites associated with each of the three selected clinical indices are  
230 depicted in Figure 4C. Remarkably, hexanoylcarnitine and cytosine, which we earlier  
231 showed to be upregulated in COVID-19, were among the 20 metabolites associated with  
232 all three of these clinical indices. This finding supports the potential utility of  
233 hexanoylcarnitine and cytosine not only as biomarkers for COVID-19 but also as  
234 predictors of disease severity.

235 Clustering of clinical indices according to their correlation with proteins also revealed two  
236 broad clusters (Figure 4E) that were notably similar to the metabolite-derived clusters,  
237 except that age and kidney disease clustered together with laboratory markers of  
238 inflammation. Volcano plots of three representative indices (death, ferritin level and  
239 platelet count) are depicted in Figure 4F. Seventeen proteins correlated with death, 26  
240 with platelet count and 29 with ferritin. Six proteins were associated with both death and  
241 ferritin level, 9 with death and platelet count, and 5 (ANGPT1, PDGF subunit A, PDGF



242 subunit B, LAP TGF-beta-1, CXCL5) with death, ferritin level and platelet count  
243 (Figure 4F). ANGPT1, PDGF subunit A and PDGF subunit B are markers of endothelial  
244 injury and platelet dysfunction while LAP, TGF-beta-1 and CXCL5 are markers of  
245 inflammation. The fact that these proteins correlated with known clinical indices of  
246 COVID-19 mortality and morbidity corroborates the importance of vascular injury and  
247 inflammation in COVID-19 pathogenesis, which we observed in our network analysis  
248 above.

249

### 250 **Metabolomics signature predicts clinical outcomes in COVID-19.**

251 We devised a novel hierarchical composite outcome measure for COVID-19 severity  
252 which incorporates a series of clinical events, ranked in order of severity, that characterize  
253 both acute COVID-19 and some of the sequelae of COVID-19 seen in post-acute COVID-  
254 19 syndrome (PACS)(42): in-hospital mortality, mechanical ventilation (MV) at discharge,  
255 kidney replacement therapy (KRT) at discharge, prolonged organ failure support  
256 (mechanical ventilation and/or kidney replacement therapy for more than 2 weeks),  
257 supplemental oxygen requirement, acute kidney injury and length of hospital stay  
258 (Figure 5A,). Our measure represents each patient on a continuous spectrum of severity  
259 to provide more information than a dichotomous classification such as mortality. Details  
260 on the design of this score and patient numbers in each group can be found in  
261 Supplementary Figure 3.

262 A machine learning algorithm based on an ordinal response mixed effect model with  
263 LASSO regularization was used to generate our prediction model of the composite  
264 outcome measure using serum metabolic profiles and baseline patient demographics  
265 (age, sex and BMI) as combined inputs (Figure 5B). Proteins were not included in the  
266 model, since our study had around three times more metabolomics samples than  
267 proteomics samples. The final model included 32 metabolites and achieved an average  
268 concordance-index of  $d=0.69$  (SE=0.017, 95% CI of [0.65, 0.72]), which is equivalent to  
269 a receiver operating characteristics area under the curve (ROC-AUC) on a binary  
270 outcome. This was a significant improvement (p-value =  $3E-5$ ) over a baseline model  
271 containing only age, sex, and BMI, which had a performance of  $d=0.59$  (SD=0.02, 95%

272 CI of [0.56, 0.64]). The 32 metabolites in the final model included 14 amino acids, 6  
273 nucleotides, 6 lipids and 2 metabolites related to energy metabolism (Figure 5C).  
274 Interestingly, our metabolite-based model showed improvement over the baseline model  
275 not only for predicting the composite outcome, but also for predicting some of its individual  
276 components (i.e., intubation, AKI, supplemental oxygen requirement, and length of  
277 hospital stay, Figure 5D).

278 We assessed the tradeoff between the number of metabolites incorporated into the model  
279 and the model's prediction performance across a range of included metabolites. Our  
280 analysis revealed that most of the predictive power ( $d \sim 0.68$ ) was already achieved with  
281 the first six metabolites (cis-aconitic acid, hydrocinnamic acid, pantothenic acid,  
282 7-methylguanosine, citrulline, methionine sulfoxide), after which prediction performance  
283 did not significantly improve (Supplementary Figure 4). This finding suggests that a  
284 targeted assay of six metabolites could predict disease severity with this accuracy,  
285 although independent validation in other datasets remains to be established.

286 As a validation step, we tested the performance of our reduced six-metabolite model on  
287 blood metabolomics data from two previously published studies by Su et al.(43) and Shen  
288 et al.(44) (Figure 5E). The Su study reported COVID-19 severity using a WHO-based  
289 score with 7 ordinal levels from mild to severe. Our model achieved a concordance index  
290 of  $d=0.83$ , again outperforming a model that just consisted of age, sex, and BMI  
291 (Figure 5E, left). The Shen study differentiated two groups of COVID-19 patients, mild  
292 and severe. That study also developed a prediction model, and we extracted their patient  
293 prediction scores from the paper to be able to calculate a concordance index for  
294 comparison. The models were tested on two test cohorts, called 'C2' and 'C3' from the  
295 original publication (Figure 5E, right). Our 6-metabolite model consistently outperformed  
296 both the score from Shen et al. as well as the baseline model with age, sex, and BMI.  
297 Notably, overall concordance scores in the Shen dataset were substantially higher than  
298 in our own dataset, both as reported in the original paper as well as in the validation of  
299 our own model on their data. We believe this effect occurs due to the complex nature of  
300 our composite outcome score as opposed to a simple yes vs. no classification of severity,  
301 the small sample size in Shen et al., and the reporting of an unvalidated training set AUC

302 of 0.95 in their study. Overall, this analysis demonstrates that the model replicates in  
303 independent datasets with varying definitions of severity, and that our model provides  
304 slightly better results compared to the previously reported prediction model.

305

## 306 **Conclusion**

307 The novel coronavirus has ravaged the global healthcare system due to its high  
308 transmissibility and unpredictable clinical course that often affects multiple organ  
309 systems. Moreover, the long-term consequences of COVID-19 infection remain poorly  
310 understood. A full understanding of the pathogenesis of COVID-19 will require an  
311 unraveling of the mechanisms of inflammation, immune dysfunction, endothelial cell injury  
312 and dysregulated coagulation that underlie this disease.

313 In our study, we used an integrative proteomic-metabolomic analysis to identify global  
314 molecular signatures specific to the acute illness of COVID-19, while many prior  
315 metabolomic and proteomic studies have not assessed the interplay between proteins  
316 and metabolites. Our analyses establish associations of specific inflammation and  
317 vascular injury-related proteins with various metabolites during COVID-19, which appear  
318 to link inflammation with mitochondria-dependent energy metabolism and viral replication,  
319 as well as coagulation with fibrogenesis and glycolysis.

320 Our discovered network modules not only provide a better understanding of disease  
321 pathogenesis, but also facilitate novel potential therapeutic targets for COVID-19. The  
322 modules identified various proteins and metabolites involved in inflammatory and vascular  
323 injury processes, such as MMP 12, Cathepsin D and RAGE which, to the best of our  
324 knowledge, have not yet been studied as targets for therapeutic intervention in COVID-19.  
325 Of note, our modules contained IL-6, which is already a mainstay of treatment for severe  
326 disease(50), and several other molecules such as carnitine, niacinamide and IFN-gamma  
327 which others have been studying in the context of COVID-19 therapies(51-53).

328 There is increasing evidence that evaluating symptoms and multiple clinical outcomes  
329 during acute disease is crucial in determining the risk of long COVID-19(54). To the best  
330 of our knowledge, we are the first group to develop a composite outcome measure in

331 COVID-19 using multiple clinical indices in a prediction model that assesses not only  
332 COVID-19 disease severity but also the sequelae of COVID-19 that characterize post-  
333 acute COVID-19 syndrome (PACS). Compared to dichotomous outcome measures such  
334 as death and survival, our composite outcome score reflects a broader, more holistic  
335 assessment of COVID-19 morbidity in the hospital setting. Moreover, we were able to  
336 validate the model in two independent studies, thereby demonstrating its generalizability  
337 and translational potential.

338 Several key strengths underlie our study cohort. As opposed to the use of healthy controls  
339 reported in other COVID-19 studies(9, 20, 43, 44, 55), our use of non-COVID patient  
340 samples, in the same hospital during the same period between March and April 2020,  
341 allowed us to investigate the interactions highly relevant to COVID-19 pathogenesis and  
342 clinical course. Additionally, we analyzed a relatively larger cohort compared to other  
343 studies, with hundreds of samples available for both metabolomic and proteomic analysis.

344 Our study has several limitations. As alterations in proteome and metabolome were  
345 analyzed in sera but not in lung tissues or bronchoalveolar lavage fluid, our results may  
346 not reflect what occurs at tissue-specific cellular levels. Furthermore, based on the current  
347 study design and methodology, the correlative relationships we report between  
348 metabolomic, and proteomic alterations and SARS-CoV-2 outcomes should be  
349 interpreted as purely correlative rather than causal in nature. Additional studies are  
350 required to define the mechanistic roles of individual molecules highlighted in this paper.  
351 Finally, as our study was only a single center investigation, our results will need to be  
352 validated in other cohorts.

353 In conclusion, our investigation has sought to not only define the metabolomic and  
354 proteomic signatures of COVID-19, but also to explore interactions between metabolites  
355 and proteins that can serve as a roadmap for future mechanistic studies. We have  
356 furthermore proposed a novel clinical composite outcome score that can be used in a  
357 clinical prediction model for COVID-19. Ultimately, a better understanding of the  
358 pathophysiology of COVID-19 at the molecular level may lead to short-term and long-  
359 term targeted therapies.

360

## 361 **Methods**

### 362 **Cohort description**

363 This is a single-center prospective analysis of one cohort comparing hospitalized COVID-  
364 19 patients and non-COVID-19 controls. Our cohort was comprised of 330 patients with  
365 confirmed SARS-CoV-2 RT-PCR, and 97 non-COVID-19 controls with negative RT-PCR  
366 results who were hospitalized at the NewYork-Presbyterian Hospital/Weill Cornell  
367 Medical Center between March and April 2020. This study has been approved by the  
368 Weill Cornell Medicine (WCM) IRB with protocol #19-10020914. Remnant serum samples  
369 were matched with selected patients after which patients were deidentified. Controls  
370 were randomly selected patients admitted to the hospital with symptoms suspicious for  
371 COVID-19, but with negative SARS-CoV-2 RT-PCR. Seventy nine percent of control  
372 group patients had shortness of breath, fever, cough or chest pain which are commonly  
373 seen in COVID-19. Children (less than 18 years old) and pregnant women (confirmed by  
374 a positive beta-HCG test and/or medical records) were excluded.

375

### 376 **Sample handling**

377 Standard practices for serum collection and storage at the NewYork-Presbyterian/Weill  
378 Cornell Medical College include collecting venous blood into a serum-separating tube  
379 (SST), and serum is obtained by centrifuging at 1,500g for 7 minutes as soon as possible  
380 with a maximum time limit of 2 hours from the time of collection. The specimens are  
381 typically stored at 4°C for 1 to 5 days before coded/de-identified and then transferred into  
382 a -80°C freezer. Samples were thawed and inactivated in different ways: for the  
383 metabolomic analysis, x3 sample volume of HPLC grade ethanol were added; for the  
384 proteomic analysis, the samples were heat-inactivated in a water bath of 56°C for 15  
385 minutes. After these processes, the samples were stored again at -80°C until the analyses  
386 were performed.

387

### 388 **Data Collection**

389 Data were obtained from the Weill Cornell Medicine COVID Institutional Data Repository  
390 (COVID-IDR), which is a high-quality registry of COVID-19 patients at NewYork-

391 Presbyterian - Cornell with laboratory confirmed SARS-CoV-2 RT-PCR. The COVID-IDR  
392 houses both manually and automatically extracted Electronic Health Record (EHR) data.  
393 Demographics, comorbidities, and important dates of patients' hospital course  
394 (admission, intubation, extubation, discharge, death) were extracted by a team of medical  
395 professionals and stored in the COVID-IDR. Laboratory tests, ventilation parameters, vital  
396 signs, and respiratory variables were additionally available via automated extraction  
397 through the Weill Cornell-Critical Care Database for Advanced Research (WC-CEDAR)  
398 within the COVID-IDR. WC-CEDAR(56) is a critical care database originally designed to  
399 automatically extract, transform, and store EHR data on Intensive Care Unit (ICU)  
400 patients; it was expanded to include all hospitalized patients during New York City's  
401 COVID-19 surge. Data not available within WC-CEDAR were manually extracted and  
402 recorded in REDCap.

403

#### 404 **Metabolomic profiling**

405 Targeted Metabolite profiling was performed according to a method described in a  
406 previous publication (57). For metabolite extraction, 80  $\mu\text{L}$  of pre-chilled methanol ( $-80\text{ }^{\circ}\text{C}$ )  
407 was added to 20  $\mu\text{L}$  of serum. The sample was vortexed for 1 min and then incubated at  
408  $-80\text{ }^{\circ}\text{C}$  for 2 hours before it was centrifuged at 20,000 g for 15 min at  $4\text{ }^{\circ}\text{C}$  to remove the  
409 pellet. The supernatant was transferred to a new Eppendorf tube and dried completely  
410 with a Speedvac for 30 min (with heat off). The dried sample was redissolved in HPLC  
411 grade water before it was applied to the hydrophilic interaction chromatography LC-MS.  
412 The sample injection order was randomized.

413 Metabolites were measured on a Q Exactive Orbitrap mass spectrometer (Thermo  
414 Scientific), which was coupled to a Vanquish UPLC system (Thermo Scientific) via an Ion  
415 Max ion source with a HESI II probe (Thermo Scientific). A Sequant ZIC-pHILIC column  
416 (2.1 mm i.d.  $\times$  150 mm, particle size of 5  $\mu\text{m}$ , Millipore Sigma) was used for separation of  
417 metabolites. A 2.1  $\times$  20 mm guard column with the same packing material was used for  
418 protection of the analytical column. Flow rate was set at 150  $\mu\text{L}/\text{min}$ . Buffers consisted of  
419 100% acetonitrile for mobile phase A, and 0.1%  $\text{NH}_4\text{OH}/20\text{ mM CH}_3\text{COONH}_4$  in water for  
420 mobile phase B. The chromatographic gradient ran from 85% to 30% A in 20 min followed  
421 by a wash with 30% A and re-equilibration at 85% A. The column temperature was set to

422 30 °C and the autosampler temperature was set to 4 °C. The Q Exactive was operated in  
423 full scan, polarity-switching mode with the following parameters: the spray voltage 3.0 kV,  
424 the heated capillary temperature 300 °C, the HESI probe temperature 350 °C, the sheath  
425 gas flow 40 units, the auxiliary gas flow 15 units. MS data acquisition was performed in  
426 the m/z range of 70–1,000, with 70,000 resolution (at 200 m/z). The AGC target was  
427 3,000,000 and the maximum injection time was 100 ms. The MS data was processed  
428 using XCalibur 4.1 (Thermo Scientific) to extract the metabolite signal intensity for relative  
429 quantitation. Metabolites were identified using an in-house library established using  
430 chemical standards. Identification required exact mass (within 5ppm) and standard  
431 retention times. As a quality control, a mixture of standard compounds was injected  
432 thirteen times throughout the LC-MS data acquisition process for monitoring of the  
433 stability of LC retention time, the MS mass accuracy and the signal intensity. The median  
434 coefficient of variation for metabolite quantitation based on the quality control sample was  
435 0.061. The data from the serum samples showed that both retention time and mass  
436 accuracy were highly stable throughout the experiment (Supplementary Figure 5).

### 437 **Proteomic profiling**

438 Proteomics analysis was performed using the Olink platform (Uppsala, Sweden) at the  
439 Proteomics Core of Weill Cornell Medicine-Qatar, according to manufacturer's  
440 instructions. We used the Inflammation, Cardiovascular II and Cardiovascular III panels.  
441 High throughput real-time PCR of reporter DNA lined to protein specific antibodies was  
442 performed on a 96-well integrated fluidic circuits chip (Fluidigm, San Francisco, CA). Each  
443 sample was spiked with quality controls to monitor the incubation, extension, and  
444 detection steps of the assay. Additionally, samples representing external, negative, and  
445 inter-plate controls were included in each analysis run. From raw data, real time PCR  
446 cycle threshold (Ct) values were extracted using Fluidigm reverse transcription  
447 polymerase chain reaction (RT-PCR) analysis software at a quality threshold of 0.5 and  
448 linear baseline correction. Ct values were further processed using the Olink NPX manager  
449 software (Olink, Uppsala, Sweden). Here, log<sub>2</sub>-transformed Ct values from each sample  
450 and analyte were normalized based on spiked-in extension controls and scale-inverted to  
451 obtain Normalized log<sub>2</sub>-scaled Protein Expression (NPX) values. NPX values were

452 adjusted based on the median of inter plate controls (IPC) for each protein and intensity  
453 median scaled between all samples and plates.

454 Each metabolite and protein was annotated with pathways from the Kyoto Encyclopedia  
455 of Genes and Genomes (KEGG) database(59).

456

### 457 **Data preprocessing**

458 Children, pregnant women, and samples after intubation were excluded from all analyses.  
459 The metabolomics data was measured in three different batches. For each batch, data  
460 was preprocessed by filtering out samples with more than 50% missing values, followed  
461 by filtering out metabolites with more than 25% missing values, probabilistic quotient  
462 normalization(60), and log<sub>2</sub> transformation. Two extreme outlier metabolites were  
463 manually removed (phosphorylcholine and adenosine monophosphate). The next step  
464 was to merge the different batches into a joint dataset. Batch 3 contained only control  
465 patients and could thus not be simply added by batch correction. To avoid issues created  
466 by this imbalanced experimental design, batches 2 and 3 contained an overlapping set of  
467 samples which were used for an anchor-based normalization by dividing each metabolite  
468 in batch 3 by the mean fold change of the overlapping samples. The anchor samples from  
469 batch 3 were then deleted and the batches combined using median-based batch  
470 correction(61). Overall, this procedure eliminates batch effects and allows for a batch that  
471 only contains control samples. Missing values were then imputed using the k-nearest  
472 neighbor approach(61).

473 Proteomics data preprocessing included the same steps of filtering, quotient  
474 normalization, logging, and missing value imputation with identical parameters as for the  
475 metabolomics data. Ten proteins were measured as duplicates on the Olink platform, so  
476 their expression values were averaged.



477

## 478 **Statistical analysis**

479 Differential expression of metabolites and proteins for both the COVID-19 vs. control  
480 analysis as well as the clinical parameter analysis within the COVID-19 cohort was  
481 assessed using the following linear mixed effect model:

$$482 \quad \text{met\_prot} \sim \text{outcome} + \text{time} + (1|\text{patient}),$$

483 where *met\_prot* is each individual metabolite or protein, *outcome* is either COVID-19  
484 yes/no or the value of a clinical parameter, *time* is the day of sample taking as a factor,  
485 and  $(1|\text{patient})$  is a random effect per patient to account for repeated measurements.  
486 P-values are reported for the significance of the outcome term.

487 Data preprocessing and statistical analysis was performed using the “maplet” toolbox for  
488 R(62) (<https://github.com/krumseklab/maplet>).

489

## 490 **Network construction**

491 The dataset was first reduced to the samples that overlap between metabolomics and  
492 proteomics (n=227), and corrected for age, sex, BMI, and COVID-19 status (yes/no). A  
493 Gaussian Graphical Model (GGM) based network was then constructed using the  
494 GeneNet algorithm(63) and drawing an edge for all partial correlations with an FDR  
495 smaller than 0.2. In a second step, this network was condensed to highlight the  
496 connections between molecules that were significantly different between COVID-19 and  
497 controls. To this end, a shortest-path distance matrix between all molecules was  
498 constructed and subset to the significant molecules. A minimum spanning tree(64) of this  
499 matrix was then constructed to visualize a simplified network.

500

## 501 **Composite Outcome**

502 A detailed description of the construction of the composite outcome along with patient  
503 numbers in each group can be found in Supplementary Figure 3.

## 504 **Regularized linear mixed effect ordinal regression model**

505 A new regression model was developed to deal with an ordinal outcome, repeated  
506 measurements, and feature selection with regularization. Repeated measurements are  
507 handled as a random effect, while age, sex, BMI, and metabolites are treated as fixed  
508 effects. The metabolites are penalized using an  $L_1$  LASSO-type regularization to obtain a  
509 sparse solution. The model is fitted using an mixed-effect ordinal regression model with  
510 complementary log-log link function(65), using maximum likelihood (ML) estimation as  
511 proposed by Ripatti and Pamgren(66). An optimal LASSO penalty parameter was  
512 estimated through an iterative algorithm for maximizing the Laplace approximation of the  
513 integrated model likelihood. This approach was adapted from Therneau(67), which was  
514 originally developed for mixed effect Cox models. To obtain an unbiased estimate of the  
515 model performance, leave-one-out-cross-validation across the entire dataset was  
516 performed. The added value of metabolomics data over baseline clinical data was  
517 assessed by comparing the final model with a model only consisting of age, sex, and BMI.

518

## 519 **Validation datasets**

520 Metabolomics data were downloaded from Su et al.(43) (n=121) and Shen et al. (44) (  
521 containing two validation sets, n=10 and n=19). The Su dataset contained all six  
522 metabolites from our reduced model as well as age, sex and BMI as baseline parameters.  
523 The Shen study also covered age, sex and BMI, and the first test dataset (“C2”) contained  
524 all six metabolites. The second test dataset (“C3”) was measured using a targeted assay  
525 of only 7 metabolites and 22 proteins, and the metabolites did not overlap with our model  
526 metabolites. Thus, we had to follow a more complex procedure for validation. We first  
527 applied our risk score in their training cohort, which contained all metabolites. In the  
528 training cohort, this score was then regressed on the available measurements in C3, i.e.  
529 modeling ‘score  $\sim$  metabolite1 + ... + metabolite7 + protein1 + ...+ protein22’. The  
530 coefficients from this model were then used in C3 to derive a surrogate severity score,  
531 which we evaluated in Figure 5.

532

533

## 534 **Data Availability**

535 The data used in this study can be downloaded at  
536 <https://doi.org/10.6084/m9.figshare.19115972.v1>.

537

### 538 **Code Availability**

539 Code to reproduce all the statistical results presented in this paper is available at  
540 <https://github.com/krumsekielab/covid-omics>.

541

### 542 **Funding**

543 JK is supported by the National Institute of Aging of the National Institutes of Health under  
544 award 1U19AG063744. SJC is supported by National Heart, Lung and Blood Institute  
545 under award K08HL138285. KS is supported by 'Biomedical Research Program' funds at  
546 Weill Cornell Medical College in Qatar, a program funded by the Qatar Foundation and  
547 multiple grants from the Qatar National Research Fund (QNRF).

548

### 549 **References**

- 550 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus  
551 Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-20.
- 552 2. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic  
553 SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020;382(22):2081-  
554 90.
- 555 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of  
556 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*.  
557 2020;395(10229):1054-62.
- 558 4. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in  
559 patients hospitalized with COVID-19. *Kidney Int*. 2020;98(1):209-18.
- 560 5. Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. *The Lancet*  
561 *Gastroenterology & Hepatology*. 2020;5(5):428-30.
- 562 6. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in  
563 Hospitalized Patients With COVID-19 in a New York City Health System. *JAMA*. 2020.
- 564 7. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor  
565 prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(4):844-7.
- 566 8. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and  
567 comorbidities in hospitalized patients with COVID-19. *Scientific Reports*. 2021;11(1):4263.
- 568 9. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal  
569 immunological misfiring in severe COVID-19. *Nature*. 2020;584(7821):463-9.

- 570 10. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission,  
571 Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020;324(8):782-  
572 93.
- 573 11. Wu P, Chen D, Ding W, Wu P, Hou H, Bai Y, et al. The trans-omics landscape of COVID-19.  
574 *Nature Communications*. 2021;12(1):4543.
- 575 12. Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19 infection  
576 alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. *JCI Insight*.  
577 2020;5(14).
- 578 13. Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, Cappellano G, et al. Large-Scale Plasma  
579 Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.  
580 *International Journal of Molecular Sciences*. 2020;21(22):8623.
- 581 14. Törnquist K, Asghar MY, Srinivasan V, Korhonen L, Lindholm D. Sphingolipids as Modulators of  
582 SARS-CoV-2 Infection. *Frontiers in Cell and Developmental Biology*. 2021;9.
- 583 15. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus  
584 Remdesivir for Hospitalized Adults with Covid-19. *New England Journal of Medicine*. 2020;384(9):795-  
585 807.
- 586 16. Iastrebnier M, Castro J, Garcia Espina E, Lettieri C, Payaslian S, Cuesta MC, et al. Ruxolitinib in  
587 severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to  
588 investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory  
589 syndrome. *Rev Fac Cien Med Univ Nac Cordoba*. 2021;78(3):294-302.
- 590 17. Roberts I, Wright Muelas M, Taylor JM, Davison AS, Xu Y, Grixiti JM, et al. Untargeted  
591 metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and  
592 outcome. *Metabolomics*. 2021;18(1):6.
- 593 18. Valdés A, Moreno LO, Rello SR, Orduña A, Bernardo D, Cifuentes A. Metabolomics study of  
594 COVID-19 patients in four different clinical stages. *Scientific Reports*. 2022;12(1):1650.
- 595 19. Meoni G, Ghini V, Maggi L, Vignoli A, Mazzoni A, Salvati L, et al. Metabolomic/lipidomic profiling  
596 of COVID-19 and individual response to tocilizumab. *PLOS Pathogens*. 2021;17(2):e1009243.
- 597 20. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al. Large-  
598 Scale Multi-omic Analysis of COVID-19 Severity. *Cell Systems*. 2021;12(1):23-40.e7.
- 599 21. Di B, Jia H, Luo OJ, Lin F, Li K, Zhang Y, et al. Identification and validation of predictive factors  
600 for progression to severe COVID-19 pneumonia by proteomics. *Signal Transduction and Targeted*  
601 *Therapy*. 2020;5(1):217.
- 602 22. Gisby J, Clarke CL, Medjeral-Thomas N, Malik TH, Papadaki A, Mortimer PM, et al. Longitudinal  
603 proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death.  
604 *Elife*. 2021;10:e64827.
- 605 23. Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Gaussian graphical modeling reconstructs  
606 pathway reactions from high-throughput metabolomics data. *BMC Syst Biol*. 2011;5:21.
- 607 24. Krumsiek J, Suhre K, Evans AM, Mitchell MW, Mohny RP, Milburn MV, et al. Mining the  
608 unknown: a systems approach to metabolite identification combining genetic and metabolic information.  
609 *PLoS Genet*. 2012;8(10):e1003005.
- 610 25. Benedetti E, Pučić-Baković M, Keser T, Wahl A, Hassinen A, Yang JY, et al. Network inference  
611 from glycoproteomics data reveals new reactions in the IgG glycosylation pathway. *Nat Commun*.  
612 2017;8(1):1483.
- 613 26. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10,  
614 CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. *Cancer Treat Rev*.  
615 2018;63:40-7.

- 616 27. Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, Bonnefont J-P. A Deficiency of Carnitine–  
617 Acylcarnitine Translocase in the Inner Mitochondrial Membrane. *New England Journal of Medicine*.  
618 1992;327(1):19-23.
- 619 28. Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from  
620 human and animal studies. *Biosci Rep*. 2015;36(1):e00281.
- 621 29. Vella F. *The metabolic and molecular bases of inherited disease seventh edition*: Edited by C R  
622 Sriver, A L Beaudet, W S Sly and D Valle. P 4605. McGraw-Hill, New York. 1995. ISBN 0-07-909826-6.  
623 *Biochemical Education*. 1996;24(1):65-.
- 624 30. León G, Herrera M, Vargas M, Arguedas M, Sánchez A, Segura Á, et al. Development and  
625 characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of  
626 COVID-19. *Sci Rep*. 2021;11(1):9825.
- 627 31. Soliman S, Faris ME, Ratemi Z, Halwani R. Switching Host Metabolism as an Approach to  
628 Dampen SARS-CoV-2 Infection. *Ann Nutr Metab*. 2020;76(5):297-303.
- 629 32. McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation  
630 syndrome in the COVID-19 era. *Nature Reviews Rheumatology*. 2021;17(3):145-57.
- 631 33. Hoelzer K, Shackelton LA, Parrish CR. Presence and role of cytosine methylation in DNA viruses  
632 of animals. *Nucleic Acids Res*. 2008;36(9):2825-37.
- 633 34. Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL. Metabolic rewiring of  
634 macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed  
635 CD47-mediated 'don't-eat-me' signal. *Nature Immunology*. 2019;20(3):265-75.
- 636 35. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial  
637 cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-8.
- 638 36. Xu S, Gu M, Wu K, Li G. Unraveling the Role of Hydroxyproline in Maintaining the Thermal  
639 Stability of the Collagen Triple Helix Structure Using Simulation. *The Journal of Physical Chemistry B*.  
640 2019;123(36):7754-63.
- 641 37. Takeshita A, Yasuma T, Nishihama K, D'Alessandro-Gabazza CN, Toda M, Totoki T, et al.  
642 Thrombomodulin ameliorates transforming growth factor- $\beta$ 1-mediated chronic kidney disease via the G-  
643 protein coupled receptor 15/Akt signal pathway. *Kidney International*. 2020;98(5):1179-92.
- 644 38. Monickaraj F, McGuire P, Das A. Cathepsin D plays a role in endothelial–pericyte interactions  
645 during alteration of the blood–retinal barrier in diabetic retinopathy. *The FASEB Journal*. 2018;32(5):2539-  
646 48.
- 647 39. Leung SWS, Shi Y. The glycolytic process in endothelial cells and its implications. *Acta*  
648 *Pharmacologica Sinica*. 2021.
- 649 40. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary  
650 Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New England Journal of Medicine*.  
651 2020;383(2):120-8.
- 652 41. Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood Glucose: A Systematic  
653 Review and Meta-Analysis. *Frontiers in Endocrinology*. 2020;11(732).
- 654 42. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute  
655 COVID-19 syndrome. *Nature Medicine*. 2021;27(4):601-15.
- 656 43. Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al. Multi-Omics Resolves a Sharp Disease-  
657 State Shift between Mild and Moderate COVID-19. *Cell*. 2020;183(6):1479-95.e20.
- 658 44. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic Characterization of  
659 COVID-19 Patient Sera. *Cell*. 2020;182(1):59-72 e15.

- 660 45. Senn S, editor *Dichomania: An Obsessive Compulsive Disorder that is Badly Affecting the*  
661 *Quality of Analysis of Pharmaceutical Trials*2005.
- 662 46. Roozenbeek B, Lingsma HF, Perel P, Edwards P, Roberts I, Murray GD, et al. The added value  
663 of ordinal analysis in clinical trials: an example in traumatic brain injury. *Crit Care*. 2011;15(3):R127.
- 664 47. Song JW, Lam SM, Fan X, Cao WJ, Wang SY, Tian H, et al. Omics-Driven Systems Interrogation  
665 of Metabolic Dysregulation in COVID-19 Pathogenesis. *Cell Metab*. 2020;32(2):188-202.e5.
- 666 48. Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, et al. Metabolomic  
667 analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. *Cell Death Dis*.  
668 2021;12(3):258.
- 669 49. López-Hernández Y, Monárrez-Espino J, Oostdam AH, Delgado JEC, Zhang L, Zheng J, et al.  
670 Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19.  
671 *Sci Rep*. 2021;11(1):14732.
- 672 50. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *New England Journal of*  
673 *Medicine*. 2021;384(16):1491-502.
- 674 51. Li C, Ou R, Wei Q, Shang H. Carnitine and COVID-19 Susceptibility and Severity: A Mendelian  
675 Randomization Study. *Frontiers in Nutrition*. 2021;8.
- 676 52. van Laarhoven A, Kurver L, Overheul GJ, Kooistra EJ, Abdo WF, van Crevel R, et al. Interferon  
677 gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case  
678 series. *Med*. 2021;2(10):1163-70.e2.
- 679 53. Fu W, Lei C, Ma Z, Qian K, Li T, Zhao J, et al. CAR Macrophages for SARS-CoV-2  
680 Immunotherapy. *Frontiers in Immunology*. 2021;12.
- 681 54. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and  
682 predictors of long COVID. *Nature Medicine*. 2021;27(4):626-31.
- 683 55. Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, et al. Systems  
684 biological assessment of immunity to mild versus severe COVID-19 infection in humans. *Science*.  
685 2020;369(6508):1210-20.
- 686 56. Schenck EJ, Hoffman KL, Cusick M, Kabariti J, Sholle ET, Champion TR. Critical care Database  
687 for Advanced Research (CEDAR): An Automated Method to Support Intensive Care Units with Electronic  
688 Health Record Data. *J Biomed Inform*. 2021:103789.
- 689 57. Chen WW, Freinkman E, Wang T, Birsoy K, Sabatini DM. Absolute Quantification of Matrix  
690 Metabolites Reveals the Dynamics of Mitochondrial Metabolism. *Cell*. 2016;166(5):1324-37 e11.
- 691 58. Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, et al. Fenofibrate  
692 prevents skeletal muscle loss in mice with lung cancer. *Proc Natl Acad Sci U S A*. 2018;115(4):E743-e52.
- 693 59. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses  
694 and cellular organisms. *Nucleic Acids Res*. 2021;49(D1):D545-d51.
- 695 60. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust  
696 method to account for dilution of complex biological mixtures. Application in 1H NMR metabolomics. *Anal*  
697 *Chem*. 2006;78(13):4281-90.
- 698 61. Do KT, Wahl S, Raffler J, Molnos S, Laimighofer M, Adamski J, et al. Characterization of missing  
699 values in untargeted MS-based metabolomics data and evaluation of missing data handling strategies.  
700 *Metabolomics*. 2018;14(10):128.
- 701 62. Chetnik K, Benedetti E, Gomari DP, Schweickart A, Batra R, Buyukozkan M, et al. maplet: An  
702 extensible R toolbox for modular and reproducible omics pipelines2021 May 01, 2021:[arXiv:2105.04305  
703 p.]. Available from: <https://ui.adsabs.harvard.edu/abs/2021arXiv210504305C>.

- 704 63. Schäfer J, Strimmer K. A shrinkage approach to large-scale covariance matrix estimation and  
705 implications for functional genomics. *Stat Appl Genet Mol Biol*. 2005;4:Article32.
- 706 64. Prim RC. Shortest Connection Networks And Some Generalizations. *Bell System Technical*  
707 *Journal*. 1957;36(6):1389-401.
- 708 65. McCullagh P. Regression Models for Ordinal Data. *Journal of the Royal Statistical Society Series*  
709 *B (Methodological)*. 1980;42(2):109-42.
- 710 66. Ripatti S, Palmgren J. Estimation of multivariate frailty models using penalized partial likelihood.  
711 *Biometrics*. 2000;56(4):1016-22.
- 712 67. Therneau T. Coxme and the Laplace approximation 2020 [Available from: [https://cran.r-](https://cran.r-project.org/web/packages/coxme/vignettes/laplace.pdf)  
713 [project.org/web/packages/coxme/vignettes/laplace.pdf](https://cran.r-project.org/web/packages/coxme/vignettes/laplace.pdf)].

714

## 715 **Figure Legends**

716 **Fig. 1. Study outline.** Study population composed by COVID-19 patients and controls.  
717 Serum samples obtained from clinically indicated specimens during the first 72 hours of  
718 admission. Metadata obtained from electronic medical records. We obtained  
719 metabolomic and proteomic profile, after which we integrated our findings into a single  
720 network describing the associations between differentially expressed proteins and  
721 metabolites in COVID-19. We then correlated the metabolites and proteins  
722 with baseline characteristics, laboratory parameters and clinical events. Finally, we  
723 developed a novel metabolite-based prediction model for a composite outcome measure  
724 comprised of key clinical parameters including death, mechanical ventilation, initiation of  
725 dialysis, supplemental oxygen requirement, development of acute kidney injury, and  
726 length of hospital stay.

727

## 728 **Fig. 2. Metabolomics and Proteomics changes associated with COVID-19.**

729 **A**, Volcano plot showing differentially expressed metabolites between COVID-19 patients  
730 and controls at an adjusted p-value <0.05. In red, upregulated metabolites in COVID-19  
731 patients. In blue, upregulated metabolites in the control group. **B**, Top 3 differentially  
732 expressed metabolites in COVID-19 patients vs. controls based on adjusted p-  
733 values. Y axis shows log<sub>2</sub> fold changes in relation to the mean of the control group.  
734 **C**, Number of significantly regulated molecules in KEGG pathways, top 15  
735 shown. **D**, Volcano plot showing the differentially expressed proteins between COVID-19  
736 patients and controls at an adjusted p-value <0.05. **E**, Top 3 differentially expressed  
737 proteins in COVID-19 patients vs. controls based on adjusted p-values. Y axis shows log<sub>2</sub>

738 fold changes in relation to the mean of the control group. **F**, Number of significantly  
739 regulated molecules in KEGG pathways, top 15 shown.

740

741 **Fig. 3. Protein-metabolite networks in COVID-19.** Gaussian graphical model (GGM)  
742 representing the significant partial correlations between all the measured metabolites and  
743 proteins, generated by a minimum spanning tree (MST) based reduction combined with  
744 a shortest paths-based approach. The network includes all differentially expressed  
745 metabolites and proteins between COVID-19 patients and controls. Squares indicate  
746 proteins and green circles indicate metabolites. Inflammatory proteins are colored in  
747 purple, while vascular injury proteins are colored in red. Shadows represent molecule  
748 modules.

749

750 **Fig. 4. Associations of molecules with clinical indices in COVID-19.** **A**, Lollipop  
751 plot representing the number of altered metabolites for each analyzed parameter  
752 (\*Diabetes mellitus, \*\*C-reactive protein, \*\*\*Acute respiratory distress syndrome,  
753 represented by whether patients were intubated). **B**, Heatmap indicating the number  
754 of differentially expressed metabolites associated with each clinical parameter and its  
755 significance. We included 4 clinical parameter categories: demographics, comorbidities,  
756 clinical events, and laboratory parameters. **C**, Volcano plot showing detailed metabolic  
757 changes correlated to death, kidney disease and C-reactive protein. **D**, Lollipop plot  
758 representing the number of altered proteins for each analyzed parameter. **E**, Heatmap  
759 indicating the number of differentially expressed proteins on each clinical parameter and  
760 its significance, using the same 4 categories described above. Proteins are marked  
761 according to Olink panels. **F**, Volcano plot showing detailed protein changes correlated  
762 to death, platelet count and ferritin levels.

763

764 **Fig. 5. Metabolomics signature predicts clinical outcomes of COVID-19.** **A**, Scheme  
765 of the hierarchical composite outcome ranging from in-hospital mortality to length of  
766 hospital stay and disposition (MV: Mechanical ventilation, KRT: Kidney replacement  
767 therapy). **B**, Dot plot comparing the predictive performance (Concordance index) of a  
768 baseline model using age, sex, and BMI and a model including baseline plus



769 metabolites. The results show that the prediction accuracy improves when adding  
770 metabolites to the model. **C**, Bar plot showing the main altered metabolic groups included  
771 in the composite outcome score. **D**, Dot plots showing individual outcome analysis,  
772 comparing the baseline model and baseline plus metabolites added. Metabolites  
773 improve the prediction accuracy of ARDS, AKI, supplemental oxygen requirement and  
774 prolonged hospitalization. **E**, Replication analysis of our model in two independent  
775 datasets by Su et al.(43) and Shen et al.(44). This analysis was performed on the reduced  
776 6-metabolite model. The Shen et al. study developed their own model, which is plotted in  
777 black.(44)



**COVID-19 negative**  
97 patients  
97 samples



**COVID-19 positive**  
330 patients  
582 samples


**Serum samples**




**Clinical data**




**Metabolomics**  
125 metabolites




**Proteomics**  
266 proteins




**Core statistics**




**Network inference**




**Protein-metabolite network in COVID-19**








**Clinical parameter correlation analysis**




**Composite outcome prediction model**









A




B




C




D




E




F




A




B



C



D



E

